Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	8.24M 7.35M 6.85M 6.23M 11.73M 793M 11.82M 82.72M 32.19M 405M 30.92M 30.26M 1.3B	P/E 2026 *	-0.45x	P/E 2027 *	-0.43x
Enterprise Value	8.24M 7.35M 6.85M 6.23M 11.73M 793M 11.82M 82.72M 32.19M 405M 30.92M 30.26M 1.3B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	94.57%	Yield 2026 *	-	Yield 2027 *	-

08-14	Traws Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-22	Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program	CI
06-22	Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program	MT
06-15	Top Premarket Decliners	MT
06-15	Ladenburg Thalmann Downgrades Traws Pharma to Neutral From Buy, Price Target is $3	MT
06-15	Traws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell	MT
06-12	Traws Pharma Provides Regulatory Update on Influenza Program	CI
05-27	Traws Pharma Advances Novel Broad-Spectrum Combination Antiviral Agent Targeting Hantavirus And Ebola Virus Disease Outbreaks	CI
05-22	Traws Pharma Inc files for offering of up to $3.1 million in common stock	RE
05-20	Hantavirus vaccines and treatments under development	RE
05-15	Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Traws Pharma Expands Antiviral Program to Target Hantavirus Infections; Shares Up Pre-Bell	MT
05-08	Traws Pharma to advance potential clinical candidates for the treatment of Hantavirus infections	RE

06-15	Ladenburg Thalmann Downgrades Traws Pharma to Neutral From Buy, Price Target is $3	MT
12-03	HC Wainwright Initiates Traws Pharma at Buy With $8 Price Target	MT
21/04/23	HC Wainwright Upgrades Onconova Therapeutics to Buy From Neutral, Price Target is $11	MT
01/03/22	Ladenburg Thalmann Starts Onconova Therapeutics at Buy With $7 Price Target	MT
18/05/21	Onconova Therapeutics : Guggenheim Starts Onconova Therapeutics at Buy With $4 Price Target	MT

08-14	Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights	AQ
06-22	Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program	AQ
06-12	Traws Pharma Provides Regulatory Update on Influenza Program	AQ
05-27	Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks	AQ
05-15	Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results	AQ

04-14	HVIVO flambe grâce à un contrat
17/03/21	Aktien New York Schluss: Dow auf Rekordhoch - Geldpolitik bleibt locker
17/03/21	Aktien New York: Überwiegend Verluste kurz vor geldpolitischen Signalen der Fed
17/03/21	Aktien New York Ausblick: Zurückhaltung vor geldpolitischen Signale der Fed

Onconova Therapeutics Inc Share Price Nasdaq

Stocks

US68232V3069

Biotechnology & Medical Research

Valuation: Onconova Therapeutics Inc

Latest news: Onconova Therapeutics Inc

Last Transcript: Onconova Therapeutics Inc

Analysts' recommendations: Onconova Therapeutics Inc

Press Releases: Onconova Therapeutics Inc

News in other languages: Onconova Therapeutics Inc

Quotes and Performance

Managers and Directors: Onconova Therapeutics Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
Iain Dukes CEO	Chief Executive Officer	67	30/03/2025
Charles Parker DFI	Director of Finance/CFO	45	04/07/2025
Robert Redfield CTO	Chief Tech/Sci/R&D Officer	74	31/03/2024

Director	Title	Age	Since
Jack Stover CHM	Chairman	73	14/04/2025
Mary Shoemaker BRD	Director/Board Member	65	31/03/2020
Trafford Clarke BRD	Director/Board Member	68	18/12/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCONOVA THERAPEUTICS INC	-11.77%	-7.89%	-	-	8.74M
WUXI APPTEC CO., LTD.	+4.16%	+3.42%	+49.37%	+94.17%	74.16B
ARGENX SE	-0.37%	-3.88%	+19.75%	+78.35%	57.39B
LONZA GROUP AG	+1.63%	+0.98%	+3.83%	+38.21%	47.64B
REVOLUTION MEDICINES, INC.	+0.50%	+2.94%	+344.62%	+722.17%	44.29B
IQVIA HOLDINGS INC.	+3.05%	-1.80%	+28.78%	+34.51%	42.5B
BEONE MEDICINES AG	+1.00%	-1.46%	+5.17%	+111.90%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+54.06%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	+1.56%	+4.53%	+31.34%	+26.92%	28.53B
BIONTECH SE	+0.76%	-1.45%	-7.44%	-11.12%	24.34B
Average	-0.00%	-0.59%	+53.86%	+127.69%	43.39B
Weighted average by Cap.	+1.55%	-0.84%	+58.06%	+136.94%

	2026 *	2027 *
Net sales	-	-
Net income	-19.25M -17.17M -16M -14.56M -27.42M -1.85B -27.62M -193M -75.21M -946M -72.26M -70.71M -3.04B	-26.75M -23.86M -22.23M -20.23M -38.1M -2.58B -38.38M -269M -105M -1.31B -100M -98.25M -4.23B
Net Debt	-	-